<DOC>
	<DOCNO>NCT01706107</DOCNO>
	<brief_summary>The primary objective study evaluate impact early treatment Tysabri Relapsing Remitting Multiple Sclerosis ( RRMS ) participant quality life ( QoL ) measure Multiple Sclerosis Impact Scale-29 ( MSIS-29 ) 2 year . The secondary objective study : evaluate impact early treatment Tysabri RRMS participants 2 year follow : annualized relapse rate ( ARR ) , Expanded Disability Status Scale ( EDSS ) , work productivity , quality life ( QoL ) EuroQol 5-Dimension questionnaire ( EQ-5D ) , QoL Subject Global Assessment Wellbeing visual analog scale ( VAS ) evaluate clinical disease-free status ( relapse , EDSS ) 2 year .</brief_summary>
	<brief_title>Canadian Multicenter Observational Study Tysabri Early Relapsing Remitting Multiple Sclerosis Participants</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<criteria>Key Ability understand purpose risk study provide sign date informed consent . Documented diagnosis Relapsing Multiple Sclerosis ( McDonald 2010 Criteria ) . Must Expanded Disability Status Scale ( EDSS ) score 0 4.0 , inclusive . Must satisfy approve therapeutic indication Tysabri per Product Monograph . Must either treatment naïve treat disease modify therapy DMT ( ) ( , limit , Avonex , Betaseron , Rebif , Copaxone , Extavia , Tecfidera and/or Gilenya ) ≤5 year total prior date inform consent . Decision treat Tysabri must precede enrollment . Key Any prior treatment Tysabri . Contraindications treatment Tysabri describe Product Monograph . History progressive multifocal leukoencephalopathy ( PML ) opportunistic infection , increase risk infection . History diagnosis Primary Progressive Multiple Sclerosis [ PPMS ] and/or Secondary Progressive Multiple Sclerosis [ SPMS ] . Receiving immunomodulatory immunosuppressive therapy . Prior history immunosuppressive use ( mitoxantrone , azathioprine , methotrexate , cyclophosphamide , mycophenolate , cladribine , rituximab ) . Immunocompromised time enrollment . Known active malignancy ( subject cutaneous basal cell carcinoma completely excise prior study entry remain eligible ) . Women breastfeed , pregnant , plan become pregnant ; woman postmenopausal surgically sterile unwilling practice contraception . Inability comply study requirement . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Quality life</keyword>
</DOC>